Study Finds Pimavanserin May Effectively Treat Parkinson Disease Psychosis

Study Finds Pimavanserin May Effectively Treat Parkinson Disease Psychosis

Publication date: Oct 06, 2019

The majority of patients with Parkinson disease develop Parkinson disease psychosis (PDPsy); however, pimavanserin may be an effective treatment option for patients, according to a recent study published by Neuropsychiatric Disease and Treatment. Researchers conducted a systematic review of randomized placebo-controlled trials comparing atypical antipsychotic with a placebo.

Databases, including PubMed, the Cochrane Library, ISI Web of Science, and Embase, were searched in order to find 13 randomized placebo-controlled trials with a total of 1142 cases involving pimavanserin, clozapine, olanzapine, and quetiapine. -Treatment of PDPsy may be difficult due to the modest efficacy of antipsychotics and the risk of worsening motor function.

-Recently, accessible antipsychotic drugs such as pimavanserin, clozapine, olanzapine, quetiapine have become of common use for the treatment of PDPsy.

Concepts Keywords
Adverse Drug Reactions Piperazines
Agranulocytosis Muscarinic antagonists
Antipsychotic Olanzapine
Antipsychotics Clozapine
Atypical Antipsychotic Quetiapine
Clozapine Mood stabilizers
Cochrane Library RTT
Embase Psychoactive drugs
ISI Chemical compounds
Leukopenia Serotonin antagonists
Meta Analysis Atypical antipsychotics
Olanzapine
Parkinson
Placebo
Psychosis
Psychotic
PubMed
Quetiapine
Randomized Controlled Trials

Semantics

Type Source Name
disease MESH defects
gene UNIPROT IMPACT
gene UNIPROT NSMAF
disease DOID leukopenia
disease DOID agranulocytosis
disease MESH leukopenia
disease MESH agranulocytosis
disease MESH adverse drug reactions
drug DRUGBANK Olanzapine
drug DRUGBANK Quetiapine
drug DRUGBANK Clozapine
disease MESH Psychosis
disease DOID Parkinson Disease
drug DRUGBANK Pimavanserin
disease MESH Parkinson Disease

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *